Next-Generation Sequencing: Scientific and Commercial Implications of the $1000 Genome

Table of Contents

A BRIEF HISTORY OF GENOME SEQUENCING TECHNOLOGY AND MILESTONES

• Dideoxy (Sanger) Sequencing
• Automated DNA Sequencing
• Genome Wars
• The $1,000 Genome

BEYOND SANGER SEQUENCING: NEXT-GENERATION SEQUENCING TECHNOLOGIES

• Sequencing-by-Synthesis/Pyrosequencing
• Sequencing-by-Synthesis
• Illumina
• GE Healthcare
• Intelligent Bio-Systems
• SOLiD (Supported Oligonucleotide Detection)
• Storage
• Polony Sequencing
• Single-Molecule Sequencing
• VisiGen
• Pacific Biosciences
• Nanopore Sequencing
• Optical Trapping
• Nanoscale Sanger Sequencing

APPLICATIONS OF NEXT-GENERATION SEQUENCING

• The $1,000 Genome/Personal Genomics
• The Cancer Genome Atlas
• Evolutionary Genomics
• Environmental Genomics
• Gene Regulation

EXPERT INTERVIEWS WITH TECHNOLOGY INNOVATORS

• Tony Smith, PhD, Illumina
• Susan Hardin, PhD, VisiGen
• Jay Shendure, MD, PhD, University of Washington, Seattle
• Kevin McKernan, ABI
• Stanley N. Lapidus, Helicos

NEXT-GENERATION COMPANIES

• Applied Biosystems
• GE Healthcare
• Helicos BioSciences
• Illumina/Solexa
• Intelligent Bio-Systems
• Pacific Biosciences
• Reveo
• Roche/454 Life Sciences
• VisiGen

CHI INSIGHT PHARMA REPORTS- NEXT-GENERATION SEQUENCING SURVEY- FEBRUARY 2007

APPENDIX

• NHGRI RESEARCH GRANTS
  • $1,000 Genome Grants (August 2005)
  • $100,000 Genome Grants

References

Company Index with Web Addresses

• Table 2.1. Next-Generation Sequencing Technologies
• Table 2.2. Features of Major Next-Generation Sequencing Platforms

• Figure 2.1. SOLiD: 2 Base Pair Encoding Using 4 Dyes
• Figure 2.2. SOLiD: Example of Decoding
• Figure 2.3. Apparatus for Single-Molecule Analysis Using Zero-Mode Waveguides
• Figure 6.1. Survey Respondents by Sector
• Figure 6.2. Primary Involvement in Next-Generation Sequencing
• Figure 6.3. Application of Next-Generation Sequencing
• Figure 6.4. Organisms Sequenced Using New Platform(s)
• Figure 6.5. Active Use of Next-Generation Sequencing Systems
• Figure 6.6. Most Promising Platform
• Figure 6.7. Chief Application of Next-Generation Sequencing
• Figure 6.8. Areas of Disease Research to Benefit from Next-Generation Sequencing
• Figure 6.9. Chief Technical Concerns about Next-Generation Sequencing
• Figure 6.10. Assessment of Current Platform Costs
• Figure 6.11. Cost of Full Human Genome Sequencing by 2010
• Figure 6.12. Dominant Platform
• Figure 6.13. Future Role of Sanger (Capillary) Sequencing
• Figure 6.14. Opinions Concerning GINA